LH Stock Recent News

Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Labcorp Holdings Inc. (NYSE:LH ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Christian O'Donnell - IR Adam Schechter - Chairman and CEO Julia Wang - EVP and CFO Conference Call Participants Michael Cherny - Leerink Partners Jack Meehan - Nephron Research Lisa Gill - JP Morgan Erin Wright - Morgan Stanley Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Patrick Donnelly - Citi Kevin Caliendo - UBS David Westenberg - Piper Sandler Tycho Peterson - Jefferies Operator Good day, and thank you for standing by. Welcome to Labcorp's Fourth Quarter 2024 Conference Call [Operator Instructions].

LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.

Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic tests.

Company Provides 2025 Guidance Results from Continuing Operations versus last year: Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billion Diluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33 Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56 Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 million Announced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024 Full-Year 2025 Guidance: Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4% Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8% Free Cash Flow of $1.10 billion to $1.25 billion; midpoint growth of 7.2% BURLINGTON, N.C. , Feb. 6, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended December 31, 2024,

Beyond analysts' top -and-bottom-line estimates for Labcorp (LH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.